InvestorsHub Logo
Followers 4
Posts 372
Boards Moderated 0
Alias Born 08/13/2019

Re: marzan post# 229023

Wednesday, 11/20/2019 8:12:51 PM

Wednesday, November 20, 2019 8:12:51 PM

Post# of 425850

Mochida already has the NASH patent prior to GILD's combo.



Regardless, by combining EPA with their drug, Gilead has a novel patentable therapy.

Edit: For example, Amarin has a patent for an all-in-one capsule of a statin-containing capsule with an EPA center. Amarin can patent the invention without taking another company's product. Does it mean Amarin can make it? No. Amarin would need a patent of a statin or permission/license from a statin patent holder.

Source: http://www.freepatentsonline.com/y2019/0099422.html

Edit 2: I just want to emphasize, this works both ways. If Gilead discovers their drug works better with Vascepa, they would need doctors to prescribe them together or license Vascepa from Amarin if they wanted to make an all-in-one drug. Does this make sense?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News